Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Blueprint Medicines Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of HCC by histological examination or by non-invasive criteria according to European Association for the Study of the Liver (EASL) or American Association for the Study of Liver Disease (AASLD) guidelines (Part 1, 2 and 3).
For Part 1 and 2, the patient has unresectable disease and has been previously treated with sorafenib, has declined treatment with sorafenib, or does not have access to sorafenib.
For Part 3, the patient has not received prior treatment with a TKI.
Child-Pugh class A with no clinically apparent ascites
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
For Part 1, willing to provide archived tumor tissue (if available) and willing to undergo pre- and on-treatment tumor biopsy (if considered safe and medically feasible by the treating investigator)
For Part 2 and 3, all patients must have an FGF19 IHC result available. Only FGF19 IHC+ HCC patients will be eligible for Part 3.
You may not be if
Central nervous system metastases
Platelet count \<75,000/mL
Absolute neutrophil count \<1000/mL
Hemoglobin \<8 g/dL
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>5x the upper limit of normal (ULN)
Total bilirubin \>2.5 mg/dL
International normalized ratio (INR) \>2.3 or prothrombin time (PT) \>6 seconds above control
Estimated (Cockroft-Gault formula) or measured creatinine clearance \<40 mL/min